Invented by Alexandra M. Capano, Pradeep Singh Tanwar, Alex Nance, Newcastle University of Upon Tyne, Ecofibre Ltd
The Newcastle University of Upon Tyne, Ecofibre Ltd invention works as followsMethods of treating ovarian carcinoma comprising: administering a patient an effective amount of a marijuana extract containing CBD, wherein the cannabis extract, preferably, is administered through a mucosal preparation.
Background for Treatment of ovarian cancer using hemp extract
Cancer is the phenotypic culmination of multiple genetic lesions which endow cells with all of the biological properties necessary for tumorigenesis.” Many cancers including gynecological tumors like ovarian cancer have complex genomic features, such as translocations and intra-chromosomal chromosome inversions. They also show point mutations, deletions or gene copy number variations. The genomic features of a cancer can determine whether it responds to a particular treatment.
Women face a variety of gynecological conditions for which there are no effective treatments. The conditions can range from benign disorders like polycystic kidney syndrome or endometriosis, to cancers that are life-altering. Cancers can invade any cells or organs of the gynecological system. Many of these cancers can be aggressive and carry a high risk of metastatic disease. This is when they spread from the cellular origin to the rest of the human body. Many gynecological tumors are resistant to chemotherapy, which means that despite aggressive treatment, the cancer does not respond to the chemotherapy. It continues to progress.
Ovarian Cancer is the second-most common gynecologic tumor in the United States, and it causes more deaths than other cancers of the female reproductive tract. The treatment for ovarian carcinoma usually includes a combination surgery and chemotherapy. As there is no screening for ovarian carcinoma, it is usually detected at a later stage of the cancer’s progression. Patients are often diagnosed with Stage 3 ovarian tumors. Stage 3 cancer is when the cancer has spread to nearby pelvic organs. The disease cannot be contained in the ovaries and fallopian tubes. The aggressiveness of the ovarian tumor and the late diagnosis of cancer have led to a five-year survival of only 39%. “The current treatment options are inadequate.
The applicant has identified treatment methods for ovarian carcinomas that include administration of cannabis-derived CBD extracts. Applicant has determined that cannabis extracts containing CBD are effective for cancers with chemosensitivity, resistance, or chemonaive characteristics, when administered either as monotherapy or in combination with other chemotherapy agents. We also advocate the therapeutic administration of cannabis extract via mucosal routes, such as the mucosa of the vaginal, oral, rectal, or nasal mucosa. “These and other embodiments will be described in more detail here.
The embodiments described herein relate to methods for treating ovarian cancer, which include administering an effective amount to a patient who is in need of such treatment.
In preferred embodiments, administering cannabis extract to a patient includes an oral or intravaginal application. In another preferred embodiment, a concomitant application of an intravaginal or rectal composition containing a cannabis-extract and concurrently administering cannabis-extract via oral dosing, or the oral mucosa is used. The combined effect produces an effective amount CBD for systemic treatments of certain cancers or gynecological conditions. In preferred embodiments the combined therapy allows for both local and systemic CBD administration, without causing harm to healthy cells.
The cannabis extracts contain one or several cannabinoids and, in particular, therapeutic amounts of CBD. They may also include additional molecules such as terpenes, cannabinoids or other molecules. In some embodiments, these methods also include therapeutic treatment for chemo-sensitive and chemo-resistant ovarian tumors. Other methods include a treatment plan that includes a cannabis-based extract and a chemotherapeutic drug. Other methods are related to the administration of cancers in ovarian tumors. These include treatment methods that use cannabis extracts containing CBD.
In one embodiment, the present patent provides a cannabis-based extract that can be used in a treatment method for ovarian cancer. The cannabis extract contains cannabidiol.
In one embodiment, the invention provides an intravaginal formulation for use in treating ovarian carcinoma in a patient. The composition includes a cannabis-extract containing cannabidiol as well as a pharmaceutically accepted excipient.
The present invention, in one embodiment, provides a cannabis-based extract that can be used in a treatment method for ovarian carcinoma in a patient. This cannabis-based extract contains cannabidiol. The term “concurrently” is defined as follows: The oral formulation is administered simultaneously with the intravaginal formula. This means that they are not more then 72 hours apart. In one embodiment, the invention provides an oral preparation for use in treating ovarian carcinoma, wherein the oral preparation comprises a cannabidiol extract (CBD), and a pharmaceutically accepted excipient. The method includes administering the oral preparation concurrently with an intravaginal composition comprising a cannabidiol extract (CBD), and a drug-acceptable excipient. In another embodiment, the invention provides an intravaginal formula for use in a treatment method for ovarian carcinoma, wherein the intravaginal formula comprises a cannabidiol extract and a drug-acceptable excipient. The method includes administering the intravaginal formula concurrently with the oral formulation that contains a cannabidiol extract and a drug-acceptable excipient.
The present invention, in one embodiment, provides a cannabis-based extract that can be used to treat ovarian carcinoma. This cannabis-based extract contains cannabidiol. The term “coadministering” is defined in this document. “Coadministering” means that the cannabis and chemotherapeutic agents are administered to the patients no longer than 72 hours, preferable no later than 48 hours and most preferably not more 24 hours. For example, the two substances should be administered no further than 12 hours, 6 hours or 4 hours apart.
The present invention, in one embodiment, provides a chemotherapeutic drug for use in a treatment method of ovarian carcinoma, said method comprising coadministering a patient a sufficient amount of the chemotherapeutic drug and a sufficient amount of a marijuana extract, said cannabis extract comprising cannabidiol.
In one embodiment, the invention provides a pharmaceutical formulation for use in a treatment method for ovarian carcinoma wherein said composition contains a cannabis-extract and an effective dose of CBD.
In one embodiment, the invention uses a cannabis-derived extract containing cannabidiol to manufacture a drug for the treatment of ovarian carcinoma.
In one embodiment, the invention provides for the use of an intravaginal formulation containing a cannabis extract containing cannabidiol in combination with a pharmaceutically accepted excipient to manufacture a drug that is used in the treatment of ovarian carcinoma.
In one embodiment, the invention uses a cannabis-derived cannabidiol in the production of a drug for the treatment of ovarian carcinoma in which said cannabis-derived cannabidiol is administered in conjunction with a chemotherapy agent.
In one embodiment, the invention uses a chemotherapeutic drug in the production of a medication for use in treating ovarian carcinoma. The chemotherapeutic drug is administered in conjunction with a cannabis-extract containing cannabidiol.
In one embodiment, the invention uses a pharmaceutical formulation containing a cannabis-extract and an effective dose of CBD to manufacture a drug for the treatment of an ovarian tumor.
In a preferred form, a cannabis-extract for use in a treatment method for ovarian cancer on a patient in which said cannabis-extract contains cannabidiol
In a further embodiment, the cannabis extract for use wherein said cannabis extract is selected from a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), a CBD isolate, and cannabidiolic acid (CBDA), optionally wherein the BSHE or FSHE comprises (i) from 50% to 99% by weight of CBD and (ii) at least one other cannabinoid selected from ?-9-tetrahydrocannabinol (?9-THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), ?-8-tetrahydrocannabinol (?8-THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.
In a further embodiment of the cannabis extract, said cannabis extract contains between 10 mg and 450 mg CBD per dosage.Click here to view the patent on Google Patents.